Most analysts and doctors were expecting the FDA to seek additional information before approving Arcoxia because Merck pulled Vioxx from the market last month after a study showed it doubled patients risk of heart attacks and strokes.
Merck withdrew its Cox-2 drug, Vioxx, from the market last month, citing a study that found it increased the risk of heart attack and stroke after 18 months of use.
Shares of Merck amp; Co. plunged more than 10 percent Monday after a media report said that documents show the pharmaceutical giant hid or denied evidence for years that its blockbuster arthritis drug
